Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04510636
Title Study of Pembrolizumab With Bendamustine in Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto

Hodgkin's lymphoma


Bendamustine + Pembrolizumab

Age Groups: adult | senior
Covered Countries CAN

No variant requirements are available.